HC Wainwright Has Positive Opinion of Ocugen FY2026 Earnings

Key Points

• HC Wainwright raised its Ocugen FY2026 EPS forecast to a loss of $0.27 from $0.28 previously, while projecting continued losses through FY2028 and profitability of $0.99 per share by FY2030.
• Ocugen shares opened at $1.09, with the company valued at approximately $369.6 million. Its latest quarterly results missed expectations, reporting a $0.07 per-share loss versus the $0.05 consensus estimate.
• Analyst sentiment remains mixed but leans positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $9.50 price target. Institutional investors own 10.27% of the stock, while the CEO recently sold shares under a pre-arranged trading plan.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Ocugen in a research report issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.27) per share for the year, up from their prior forecast of ($0.28). The consensus estimate for Ocugen's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ocugen's Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.39) EPS and FY2030 earnings at $0.99 EPS.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings raised Ocugen from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Ocugen from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ocugen has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

Ocugen Stock Up 5.8%

Shares of NASDAQ:OCGN opened at $1.09 on Wednesday. The firm has a market cap of $369.63 million, a P/E ratio of -4.19 and a beta of 2.20. Ocugen has a 12-month low of $0.97 and a 12-month high of $2.73. The business has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $1.46. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.89 million.

Institutional Investors Weigh In On Ocugen

A number of hedge funds have recently added to or reduced their stakes in OCGN. Engineers Gate Manager LP increased its holdings in shares of Ocugen by 70.2% during the second quarter. Engineers Gate Manager LP now owns 18,368 shares of the company's stock valued at $28,000 after acquiring an additional 7,577 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Ocugen by 42.4% in the 2nd quarter. NewEdge Advisors LLC now owns 237,180 shares of the company's stock worth $363,000 after purchasing an additional 70,585 shares in the last quarter. AXQ Capital LP bought a new position in shares of Ocugen in the 2nd quarter worth $65,000. Headlands Technologies LLC grew its position in Ocugen by 527.1% in the 2nd quarter. Headlands Technologies LLC now owns 511,575 shares of the company's stock valued at $783,000 after purchasing an additional 429,997 shares during the period. Finally, Two Sigma Securities LLC increased its stake in Ocugen by 116.9% during the 2nd quarter. Two Sigma Securities LLC now owns 156,027 shares of the company's stock valued at $239,000 after purchasing an additional 84,100 shares in the last quarter. Institutional investors and hedge funds own 10.27% of the company's stock.

Insider Activity at Ocugen

In related news, CEO Shankar Musunuri sold 57,264 shares of the business's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $1.12, for a total value of $64,135.68. Following the completion of the sale, the chief executive officer directly owned 1,088,035 shares of the company's stock, valued at $1,218,599.20. The trade was a 5.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.95% of the stock is currently owned by corporate insiders.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts. The firm improved its estimates for FY2026, FY2027, FY2028, and the second through fourth quarters of 2027, reflecting expectations for narrower losses. Its FY2030 forecast also increased to $0.99 earnings per share from $0.98, suggesting potential long-term profitability. Ocugen analyst estimates
• Positive Sentiment: Ocugen announced presentations at upcoming scientific conferences. Management will highlight its modifier gene therapy platform for blindness-related diseases, providing an opportunity to increase visibility with researchers, investors, and potential partners. However, the announcement did not include new clinical or regulatory results. Ocugen scientific conferences announcement
• Neutral Sentiment: Investor and industry conference appearances could support awareness. Ocugen executives are scheduled to participate in October events, including an H.C. Wainwright conference, but the company provided no specific financing, partnership, or development update. Ocugen October conference announcement
• Negative Sentiment: Ocugen is still expected to report substantial losses. HC Wainwright forecasts negative EPS of $0.27 for FY2026, $0.32 for FY2027, and $0.39 for FY2028. The firm also trimmed its FY2029 estimate to $0.05 from $0.06, tempering the otherwise favorable revisions. With a negative trailing P/E and a quick ratio of 0.80, profitability and funding remain key risks.

About Ocugen

Ocugen, Inc NASDAQ: OCGN is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company's ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Ocugen's leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.